D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; and DWR-2206, a regenerative medicine cell-product for bullous keratopathy. D. Western Therapeutics Institute, Inc. was founded in 1999 and is headquartered in Nagoya, Japan.
Research context
D. Western Therapeutics Institute, Inc appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
D. Western Therapeutics Institute, Inc is currently in a long term downtrend where the price is trading 8.9% below its 200 day moving average.
From a valuation standpoint, the stock is 64.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 24.8.
D. Western Therapeutics Institute, Inc's total revenue sank by 10.6% to $115M since the same quarter in the previous year.
Its net income has dropped by 1044.3% to $-125M since the same quarter in the previous year.
Based on the above factors, D. Western Therapeutics Institute, Inc gets an overall score of 1/5.